GlobeNewswire Inc.··Replimune Group, Inc.Replimune's Melanoma Drug Rejected by FDA Despite Promising Trial Data
Replimune receives FDA rejection for RP1 immunotherapy despite 34% response rate in trials. Company plans layoffs, blames regulatory process.
REPLFDA rejectionComplete Response Letter